We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

41 hedge funds and large institutions have $3.25M invested in VYNE Therapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.05% less ownership

Funds ownership: 0.86% → 0.8% (-0.05%)

7% less funds holding

Funds holding: 44 → 41 (-3)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

33% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 12

42% less capital invested

Capital invested by funds: $5.63M → $3.25M (-$2.38M)

Holders
41
Holders Change
-3
Holders Change %
-6.82%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
12
Closed
7
Calls
$28K
Puts
–
Net Calls
+$28K
Net Calls Change
-$60K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$149K
2
TSS
Two Sigma Securities
New York
+$59.6K
3
CAN
Cetera Advisor Networks
California
+$53.6K
4
VF
Virtu Financial
New York
+$18.7K
5
Citigroup
Citigroup
New York
+$18.1K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$154K
2
B
Bailard
California
-$91K
3
Millennium Management
Millennium Management
New York
-$88.4K
4
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$65K
5
BlackRock
BlackRock
New York
-$52.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
26
LPL Financial
California
$7K -$344 -41 -4%
TRCT
27
Tower Research Capital (TRC)
New York
$5K +$2.03K +242 +57%
TFA
28
Tobias Financial Advisors
Florida
$4K – – –
UBS Group
29
UBS Group
Switzerland
$4K +$4.76K +568 +4,057%
Federated Hermes
30
Federated Hermes
Pennsylvania
$1K – – –
Russell Investments Group
31
Russell Investments Group
United Kingdom
$1K – – –
CS
32
Credit Suisse
Switzerland
$1K +$1.14K +136 New
GCP
33
GSA Capital Partners
United Kingdom
– -$154K -13,127 Closed
B
34
Bailard
California
– -$91K -7,743 Closed
Baillie Gifford & Co
35
Baillie Gifford & Co
United Kingdom
– -$65K -5,487 Closed
Citadel Advisors
36
Citadel Advisors
Florida
– -$20.8K -2,477 Closed
HF
37
HRT Financial
New York
– -$10K -909 Closed
Jane Street
38
Jane Street
New York
– -$8K -672 Closed
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$7K -568 Closed
JP Morgan Chase
40
JP Morgan Chase
New York
– -$2.37K -282 -97%
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
– -$159 -19 -95%
Rockefeller Capital Management
42
Rockefeller Capital Management
New York
– +$8 +1 +1%
Wells Fargo
43
Wells Fargo
California
– +$25 +3 +4%
Simplex Trading
44
Simplex Trading
Illinois
– +$42 +5 New
1
2

VYNE Hedge Fund Activity: Q2 2022 in Review

41 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q2 2022, worth a combined $3.25M — down 42% from $5.63M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of VYNE and 5 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 8 added.

The largest buyer was Vanguard Group, adding an estimated $149K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $154K sold.

  • 41 institutional investors held VYNE Therapeutics (VYNE) as of Q2 2022, down from 44 in Q1 2022.
  • Funds reported $3.25M of VYNE Therapeutics stock for Q2 2022, down 42% quarter-over-quarter.
  • 5 funds opened new VYNE Therapeutics positions in Q2 2022 and 7 closed out, a net change of -2 holders.
  • The largest VYNE Therapeutics buyer in Q2 2022 was Vanguard Group, an estimated $149K added.
  • The largest VYNE Therapeutics seller in Q2 2022 was GSA Capital Partners, an estimated $154K sold.

Based on aggregated 13F filings for Q2 2022.